tbuckley/cabot-search huggingface dataset:
Anakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)*
Authors: S. Cro, V.R. Cornelius, A.E. Pink, R. Wilson, A. Pushpa‐Rajah, P. Patel, A. Abdul‐Wahab, S. August, J. Azad, G. Becher, A. Chapman, G. Dunnill, A.D. Ferguson, A. Fogo, S.A. Ghaffar, J.R. Ingram, S. Kavakleiva, E. Ladoyanni, J.A. Leman, A.E. Macbeth, A. Makrygeorgou, R. Parslew, A.J. Ryan, A. Sharma, A.R. Shipman, C. Sinclair, R. Wachsmuth, R.T. Woolf, A. Wright, H. McAteer, J.N.W.N. Barker, A.D. Burden, C.E.M. Griffiths, N.J. Reynolds, R.B. Warren, H.J. Lachmann, F. Capon, C.H. Smith, Davide Altamura, Vincent Piguet, Roberto Verdolini, Marc Wallace, Kavitha Sundararaj, Nisha Arujuna, Charlotte Fleming, Ruth Lamb, Jacqueline Dodds, Sonia Baryschpolec, Hywel Cooper
Journal: British Journal of Dermatology (2021)

Palmoplantar pustulosis (PPP) is a rare, debilitating, chronic inflammatory skin disease that affects the hands and feet. Clinical, immunological and genetic findings suggest a pathogenic role for interleukin (IL)-1.
Mismatched Lesions on 18F-FDG PET and 18F-Fluciclovine PET Images in a Patient With Metastatic Prostate Small Cell Carcinoma
Authors: Joshua Gu, Yang Lu, Guofan Xu
Journal: Clinical Nuclear Medicine (2021)

Abstract A 65-year-old man with fluciclovine-avid metastatic prostate small cell carcinoma with prostate-specific antigen (PSA) 19.4 ng/mL at diagnosis underwent system therapy and subsequent surgery and achieved hormonal response with PSA &lt;0.1 ng/mL. An 18 F-fluciclovine PET/CT scan 3 months after surgery was negative for disease. Although PSA remained &lt;0.1 ng/mL, the rising carcinoembryonic antigen prompted an 18 F-FDG PET/CT 6 weeks later. It showed multiple hypermetabolic lesions in the prostatectomy bed, liver, and right iliac bone, suggestive of malignant disease. The FDG-avid prostatectomy lesions were further confirmed on MRI. This case demonstrates that FDG PET/CT has a role in suspected metastatic prostate small cell carcinoma with negative fluciclovine PET examination.
Cytokine levels in sputum, not serum, may be more helpful for indicating the damage in the lung and the prognosis of severe COVID-19 – A case series
Authors: Changsong Wang, Kai Kang, Xiuwen Lan, Dongsheng Fei, Qian Wang, Xianyong Li, Yang Chong, Yan Gao, Huaiquan Wang, Xueting Li, Mingyan Zhao, Kaijiang Yu
Journal: Journal of Infection (2021)

PurposeTo describe the relationship between the severity of lung damage and cytokine levels in sputum, bronchoalveolar lavage fluid (BALF), serum.MethodEight severe patients infected with coronavirus disease 2019 (COVID-19) were admitted and their cytokines and chest computed tomography (CT) were analyzed.ResultsCompared with in serum, IL-6 and TNF-α in sputum and in BALF show more directly reflect the severity of COVID-19 critical patients. The gradient ratio of IL-6 levels may predict the prognosis of severe patients.ConclusionCytokine levels in the sputum may be more helpful for indicating lung damage. Local intervention through the respiratory tract is expected to benefit patients with severe COVID-19.
Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic
Authors: Susan J. Woolford, Margo Sidell, Xia Li, Veronica Else, Deborah R. Young, Ken Resnicow, Corinna Koebnick
Journal: JAMA (2021)

Anthony L. Lin, MD; Eric Vittinghoff, PhD; Jeffrey E. Olgin, MD; Mark J. Pletcher, MD, MPH; Gregory M. Marcus, MD, MAS
Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review
Authors: Helen Hall, Adam Tocock, Sarah Burdett, David Fisher, William M Ricketts, John Robson, Thomas Round, Sarita Gorolay, Emma MacArthur, Donna Chung, Sam M Janes, Michael D Peake, Neal Navani
Journal: Thorax (2021)

National targets for timely diagnosis and management of a potential cancer are driven in part by the perceived risk of disease progression during avoidable delays. However, it is unclear to what extent time-to-treatment impacts prognosis for patients with non-small cell lung cancer, with previous reviews reporting mixed or apparently paradoxical associations. This systematic review focuses on potential confounders in order to identify particular patient groups which may benefit most from timely delivery of care.
26186 Efficacy and safety of continuous risankizumab every 12 weeks beyond 3 years of follow-up: An interim analysis of the LIMMitless open-label extension trial
Authors: Kim A. Papp, Mark G. Lebwohl, Lluís Puig, Jiewei Zeng, Simone Rubant, Ranjeeta Sinvhal, Yiwei Zhao, Gabriela Alperovich, Craig Leonardi
Journal: Journal of the American Academy of Dermatology (2021)
Functional Genomic Landscape of Epigenetic Dependencies in Myeloma
Authors: Ricardo De Matos Simoes, Geoffrey Matthews, Daphne Dupere Richer, Ryosuke Shirasaki, Michal Sheffer, Olga Dashevsky, Sara Gandolfi, Eugen Dhimolea, Brian Glassner, Richard W. J. Groen, Franciska Vazquez, Joshua Dempster, Aviad Tsherniak, William C. Hahn, Aedin Culhane, Jonathan D. Licht, Constantine S. Mitsiades
Journal: Blood (2017)
A stress-induced miR-31–CLOCK–ERK pathway is a key driver and therapeutic target for skin aging
Authors: Yao Yu, Xia Zhang, Fengzhen Liu, Peiying Zhu, Liping Zhang, You Peng, Xinyu Yan, Yin Li, Peng Hua, Caiyue Liu, Qingfeng Li, Liang Zhang
Journal: Nature Aging (2021)
血液透析(HD)患者におけるβ2ミクログロブリン(β2M)アミロイドの形成へのフィブロネクチン(FN)の関与
Authors: Saito N, Miyazaki S, Haginoshita S, Sakurabayashi T, Ei R, Koda Y, Yuasa Y, Sakai S, Suzuki M, Takahashi S, Morita T, Arakawa M, Hirasawa Y
Journal: Journal of the American Society of Nephrology (1996)
Breast Density, Risk of Breast Cancer, and Screening Mammography in Women 75 Years and Older
Authors: Catherine M. Tuite
Journal: JAMA Network Open (2021)

Shailesh M. Advani, MD, PhD; Weiwei Zhu, MS; Joshua Demb, PhD; Brian L. Sprague, PhD; Tracy Onega, PhD; Louise M. Henderson, PhD; Diana S. M. Buist, PhD; Dongyu Zhang, MD, PhD; John T. Schousboe, MD, PhD; Louise C. Walter, MD; Karla Kerlikowske, MD; Diana L. Miglioretti, PhD; Dejana Braithwaite, PhD, MSc; Breast Cancer Surveillance Consortium; Brian L Sprague; Tracy Onega; Louise M Henderson; Diana SM Buist; Karla Kerlikowske; Diana L Miglioretti; WeiWei Zhu
Abstract 14451: Transcriptomics Reveal Cardioprotective Features of Arteriovenous Fistula-Induced Cardiac Hypertrophy
Authors: Shin-Rong Lee, Stephanie Thorn, Nicole Guerrera, Albert J Sinusas, Alan Dardik
Journal: Circulation (2019)

Introduction: Arteriovenous fistulae (AVF) are surgical shunts created for hemodialysis access. The high shunt rates can result in LV hypertrophy, which is thought to portend poor cardiac outcomes....
28457 Visualization of penetration of topical antifungal drug substances through mycosis-infected nails by matrix assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI)
Authors: Nicolas Joly-Tonetti, Fernanda Endringer Pinto, Charlotte Bagger, Hanan Osman-Ponchet, Christian Janfelt
Journal: Journal of the American Academy of Dermatology (2021)
Metastasis-Entrained Eosinophils Enhance Lymphocyte-Mediated Antitumor Immunity
Authors: Sharon Grisaru-Tal, Shai Dulberg, Lir Beck, Chunyan Zhang, Michal Itan, Soroor Hediyeh-zadeh, Julie Caldwell, Perri Rozenberg, Avishay Dolitzky, Shmuel Avlas, Inbal Hazut, Yaara Gordon, Ophir Shani, Shlomo Tsuriel, Motti Gerlic, Neta Erez, Nicolas Jacquelot, Gabrielle T. Belz, Marc E. Rothenberg, Melissa J. Davis, Hua Yu, Tamar Geiger, Asaf Madi, Ariel Munitz
Journal: Cancer Research (2021)

Abstract The recognition of the immune system as a key component of the tumor microenvironment (TME) led to promising therapeutics. Because such therapies benefit only subsets of patients, understanding the activities of immune cells in the TME is required. Eosinophils are an integral part of the TME especially in mucosal tumors. Nonetheless, their role in the TME and the environmental cues that direct their activities are largely unknown. We report that breast cancer lung metastases are characterized by resident and recruited eosinophils. Eosinophil recruitment to the metastatic sites in the lung was regulated by G protein–coupled receptor signaling but independent of CCR3. Functionally, eosinophils promoted lymphocyte-mediated antitumor immunity. Transcriptome and proteomic analyses identified the TME rather than intrinsic differences between eosinophil subsets as a key instructing factor directing antitumorigenic eosinophil activities. Specifically, TNFα/IFNγ–activated eosinophils facilitated CD4+ and CD8+ T-cell infiltration and promoted antitumor immunity. Collectively, we identify a mechanism by which the TME trains eosinophils to adopt antitumorigenic properties, which may lead to the development of eosinophil-targeted therapeutics. Significance: These findings demonstrate antitumor activities of eosinophils in the metastatic tumor microenvironment, suggesting that harnessing eosinophil activity may be a viable clinical strategy in patients with cancer.
Abstract 14647: Calcium Channel Blockers Exacerbate Aortic Disease and Cause Premature Lethality in Marfan Syndrome
Authors: Jefferson J Doyle, Jennifer P Habashi, Mark Lindsay, Djahida Bedja, Harry C Dietz
Journal: Circulation (2010)

Aortic root dilatation and dissection is the leading cause of death in Marfan syndrome (MFS). We previously showed that excessive TGFβ-dependent activation of ERK signaling drives aneurysm progress...
Association of Cycling With All-Cause and Cardiovascular Disease Mortality Among Persons With Diabetes—Reply
Authors: Mathias Ried-Larsen, Martin Gillies Rasmussen, Anders Grøntved
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Authors: Noam Barda, Noa Dagan, Yatir Ben-Shlomo, Eldad Kepten, Jacob Waxman, Reut Ohana, Miguel A Hernán, Marc Lipsitch, Isaac Kohane, Doron Netzer, Ben Y Reis, Ran D Balicer
Journal: New England Journal of Medicine (2021)

Preapproval trials showed that messenger RNA (mRNA)-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the safety of the BNT162b2 mRNA vaccine with respect to a broad range of potential adverse events is needed.We used data from the largest health care organization in Israel to evaluate the safety of the BNT162b2 mRNA vaccine. For each potential adverse event, in a population of persons with no previous diagnosis of that event, we individually matched vaccinated persons to unvaccinated persons according to sociodemographic and clinical variables. Risk ratios and risk differences at 42 days after vaccination were derived with the use of the Kaplan-Meier estimator. To place these results in context, we performed a similar analysis involving SARS-CoV-2-infected persons matched to uninfected persons. The same adverse events were studied in the vaccination and SARS-CoV-2 infection analyses.In the vaccination analysis, the vaccinated and control groups each included a mean of 884,828 persons. Vaccination was most strongly associated with an elevated risk of myocarditis (risk ratio, 3.24; 95% confidence interval [CI], 1.55 to 12.44; risk difference, 2.7 events per 100,000 persons; 95% CI, 1.0 to 4.6), lymphadenopathy (risk ratio, 2.43; 95% CI, 2.05 to 2.78; risk difference, 78.4 events per 100,000 persons; 95% CI, 64.1 to 89.3), appendicitis (risk ratio, 1.40; 95% CI, 1.02 to 2.01; risk difference, 5.0 events per 100,000 persons; 95% CI, 0.3 to 9.9), and herpes zoster infection (risk ratio, 1.43; 95% CI, 1.20 to 1.73; risk difference, 15.8 events per 100,000 persons; 95% CI, 8.2 to 24.2). SARS-CoV-2 infection was associated with a substantially increased risk of myocarditis (risk ratio, 18.28; 95% CI, 3.95 to 25.12; risk difference, 11.0 events per 100,000 persons; 95% CI, 5.6 to 15.8) and of additional serious adverse events, including pericarditis, arrhythmia, deep-vein thrombosis, pulmonary embolism, myocardial infarction, intracranial hemorrhage, and thrombocytopenia.In this study in a nationwide mass vaccination setting, the BNT162b2 vaccine was not associated with an elevated risk of most of the adverse events examined. The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events was substantially increased after SARS-CoV-2 infection. (Funded by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute.).
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study
Authors: Otavio T Ranzani, Matt D T Hitchings, Murilo Dorion, Tatiana Lang D’Agostini, Regiane Cardoso de Paula, Olivia Ferreira Pereira de Paula, Edlaine Faria de Moura Villela, Mario Sergio Scaramuzzini Torres, Silvano Barbosa de Oliveira, Wade Schulz, Maria Almiron, Rodrigo Said, Roberto Dias de Oliveira, Patricia Vieira da Silva, Wildo Navegantes de Araújo, Jean Carlo Gorinchteyn, Jason R Andrews, Derek A T Cummings, Albert I Ko, Julio Croda
Journal: BMJ (2021)

To estimate the effectiveness of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech), against symptomatic covid-19 in the elderly population of São Paulo state, Brazil during widespread circulation of the gamma variant.Test negative case-control study.Community testing for covid-19 in São Paulo state, Brazil.43 774 adults aged ≥70 years who were residents of São Paulo state and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 29 April 2021. 26 433 cases with symptomatic covid-19 and 17 622 test negative controls with covid-19 symptoms were formed into 13 283 matched sets, one case with to up to five controls, according to age, sex, self-reported race, municipality of residence, previous covid-19 status, and date of RT-PCR test (±3 days).Vaccination with a two dose regimen of CoronaVac.RT-PCR confirmed symptomatic covid-19 and associated hospital admissions and deaths.Adjusted vaccine effectiveness against symptomatic covid-19 was 24.7% (95% confidence interval 14.7% to 33.4%) at 0-13 days and 46.8% (38.7% to 53.8%) at ≥14 days after the second dose. Adjusted vaccine effectiveness against hospital admissions was 55.5% (46.5% to 62.9%) and against deaths was 61.2% (48.9% to 70.5%) at ≥14 days after the second dose. Vaccine effectiveness ≥14 days after the second dose was highest for the youngest age group (70-74 years)-59.0% (43.7% to 70.2%) against symptomatic disease, 77.6% (62.5% to 86.7%) against hospital admissions, and 83.9% (59.2% to 93.7%) against deaths-and declined with increasing age.Vaccination with CoronaVac was associated with a reduction in symptomatic covid-19, hospital admissions, and deaths in adults aged ≥70 years in a setting with extensive transmission of the gamma variant. Vaccine protection was, however, low until completion of the two dose regimen, and vaccine effectiveness was observe to decline with increasing age among this elderly population.
Incidence of Psoriatic Arthritis Among Patients Receiving Biologic Treatments for Psoriasis: A Nested Case–Control Study
Authors: Yael Shalev Rosenthal, Naama Schwartz, Iftach Sagy, Lev Pavlovsky
Journal: Arthritis & Rheumatology (2021)

To investigate the effect of biologic treatments for psoriasis on the incidence of psoriatic arthritis (PsA).This retrospective cohort study was conducted using electronic medical records from a large health maintenance organization. Patients who received biologic treatment for psoriasis and were not diagnosed as having PsA before or at the time of biologic treatment initiation were included. Control psoriasis patients who did not receive biologic treatment were matched by age at time of diagnosis, sex, time from psoriasis diagnosis until treatment initiation, maximum body mass index, and smoking status. The groups were different in most characteristics. Therefore, propensity score matching was implemented. Log rank test and multivariable Cox proportional hazards regression were used to compare the groups.Overall, 1,326 patients were included, of whom 663 had received biologic treatment and 663 had not. The Kaplan-Meier curve for the propensity score-matched groups reflected a statistically significant increased risk for PsA among the control group compared to the biologic treatment group. The results of the multivariable Cox regression showed that the control group had a significantly higher risk for PsA compared to the biologic treatment group within 10 years of follow-up (adjusted hazard ratio 1.39 [95% confidence interval 1.03-1.87]).Our findings show a statistically and clinically significant decreased risk for developing PsA among patients with psoriasis who receive biologic treatments. The results suggest that biologic medications should be considered for patients who present with significant risk factors for PsA at an earlier stage of treatment.
27847 Guselkumab (GUS) efficACy in TNF-inhibitor-experienced and TNF-inhibitor-naïve patients with active psoriatic arthritis (PsA): Results of a phase 3, randomized, controlled study
Authors: Christopher T. Ritchlin, Atul Deodhar, Wolf-Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, May Shawi, Ya-Wen Yang, Shihong Sheng, Prasheen Agarwal, Philip S. Helliwell
Journal: Journal of the American Academy of Dermatology (2021)
25800 Bimekizumab for the treatment of moderate to severe psoriasis of the scalp: Post hoc analysis from the BE SURE phase 3 trial
Authors: Kristian Reich, Joseph F. Merola, Boni Elewski, Kim A. Papp, Luis Puig, Pheobe Rich, Christopher Cioffi, Eva Cullen, Luke Peterson, Alice B. Gottlieb
Journal: Journal of the American Academy of Dermatology (2021)
Dysregulated expression of the human long noncoding RNA GHSROS may influence prostate cancer progression and resistance to docetaxel
Authors: Patrick B. Thomas, Penny L. Jeffery, Gahete D. Manuel, Eliza J. Whiteside, Michelle Maugham, Carina Walpole, Jennifer H. Gunter, Elizabeth D. Williams, Colleen C. Nelson, Adrian C. Herington, Raul M. Luque, Rakesh N. Veedu, Lisa K. Chopin, Inge Seim
Journal: Cancer Research (2018)

Long noncoding RNAs (lncRNAs) play key regulatory roles in cancer progression and are novel therapeutic targets. We recently discovered the lncRNA gene, GHSROS (GHSR opposite strand), on the antisense DNA strand of the ghrelin receptor gene (GHSR). Here, we studied the expression and function of GHSROS in prostate cancer. Interrogation of microarray and RNA-seq data sets revealed that (similar to other lncRNA oncogenes) GHSROS is actively transcribed, although expressed at very low levels in cancer cell lines and tissues. By quantitative RT-PCR we demonstrate that GHSROS is highly expressed in a subset of high-grade prostate cancers (~11.4%). Moreover, the lncRNA is upregulated in high Gleason-score prostate tumors in two clinical data sets. Forced GHSROS overexpression significantly increased in vitro cell proliferation and migration of PC3, DU145, and LNCaP prostate cancer cell lines (P ≤ 0.05, Student's t-test). Increased cell proliferation observed in GHSROS-overexpressing prostate cancer cell lines was recapitulated in PC3, DU145, and LNCaP prostate cancer xenografts in NOD/SCID mice. Cell survival was significantly increased in GHSROS-overexpressing LNCaP cells treated with the cytotoxic drug docetaxel (P ≤ 0.05, Student's t-test). Docetaxel treatment also increased GHSROS expression in native LNCaP and PC3 cells in a dose-dependent manner (P ≤ 0.05, Student's t-test). These data suggest that GHSROS mediates tumor survival and resistance to docetaxel. To identify fundamental drivers of the observed tumorigenic phenotype of GHSROS-overexpressing cell lines, high-throughput RNA-seq data from in vitro cultured PC3 cells and LNCaP xenografts were examined. A quarter of the genes differentially expressed by GHSROS-overexpressing PC3 cells were also differentially expressed by GHSROS-overexpressing LNCaP xenografts. These 101 genes include several transcription factors with established roles in prostate cancer (including the androgen receptor) and genes associated with metastasis and poor prognosis. Finally, we developed two distinct antisense oligonucleotides (ASOs) targeting GHSROS, achieving >60% knockdown, and their function was assessed in vitro. ASO inhibition of GHSROS expression reciprocally regulated cell growth and migration and the expression of a range of genes. These ASOs are currently being assessed in preclinical animal models. Our findings suggest that the long noncoding RNA GHSROS reprograms prostate cancer cells toward a more aggressive phenotype and that the lncRNA represents a promising therapeutic target.
27434 Early trends of disease improvement in adult patients with atopic dermatitis treated with dupilumab: Real-world data from the PROSE registry
Authors: Jerry Bagel, Gil Yosipovitch, David M. Pariser, Robert Y. Lin, Haixin Zhang, Daniel Richman, Andrew Korotzer, Shikha Bansal
Journal: Journal of the American Academy of Dermatology (2021)
血管平滑筋細胞におけるリガンド依存的上皮成長因子受容体劣化メカニズムによるアンギオテンシンIIシグナル伝達における肝細胞増殖因子/c-Met系の負の作用
Authors: Okayama K, Kusunoki H, Koibuchi N, Doi T, Aizawa Y, Morishita R, Azuma J, Sanada F, Taniyama Y, Iekushi K
Journal: Circulation Research (2009)
Randomized Clinical Trials in the Era of Precision Oncology—The Role of End Points, Industry Funding, and Medical Writing Integrity
Authors: Alessandro Rizzo, Veronica Mollica, Francesco Massari
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal